Neutropenia-Pipeline Review, H1 2015

Neutropenia-Pipeline Review, H1 2015

  • Products Id :- GMDHC6596IDB
  • |
  • Pages: 91
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Neutropenia-Pipeline Review, H1 2015


Global Markets Direct's, 'Neutropenia-Pipeline Review, H1 2015', provides an overview of the Neutropenia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neutropenia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Neutropenia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Neutropenia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Neutropenia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Neutropenia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Neutropenia Overview 9

Therapeutics Development 10

Pipeline Products for Neutropenia-Overview 10

Pipeline Products for Neutropenia-Comparative Analysis 11

Neutropenia-Therapeutics under Development by Companies 12

Neutropenia-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Neutropenia-Products under Development by Companies 19

Neutropenia-Companies Involved in Therapeutics Development 21

Apotex, Inc. 21

Biocon Limited 22

Biosidus S.A. 23

Cellerant Therapeutics, Inc. 24

Chong Kun Dang Pharmaceutical Corp. 25

Coherus BioSciences, Inc. 26

CSL Limited 27

Gamida Cell Ltd. 28

Genexine, Inc. 29

Inbiopro Solutions Pvt. Ltd. 30

Ligand Pharmaceuticals, Inc. 31

NAL Pharmaceuticals Ltd. 32

Pfenex Inc. 33

Richter Gedeon Nyrt. 34

Sandoz International GmbH 35

Taiho Pharmaceutical Co., Ltd. 36

Teva Pharmaceutical Industries Limited 37

Therapeutic Proteins International, LLC 38

Toko Pharmaceutical Industries Co., Ltd. 39

USV Limited 40

Neutropenia-Therapeutics Assessment 41

Assessment by Monotherapy Products 41

Assessment by Combination Products 42

Assessment by Target 43

Assessment by Mechanism of Action 45

Assessment by Route of Administration 47

Assessment by Molecule Type 49

Drug Profiles 51

(piperacillin sodium + tazobactam sodium)-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

ACN-8337-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

CSL-324-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

filgrastim-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

filgrastim-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

filgrastim-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

filgrastim (recombinant)-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

GC-003-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

granulocyte colony-stimulating factor biobetter-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

GXG-3-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

IBPB-004IG-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

LG-7455-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

lipegfilgrastim-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

pegfilgrastim-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

pegfilgrastim-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

pegfilgrastim-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

pegfilgrastim-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

pegfilgrastim-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

pegfilgrastim-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

pegfilgrastim-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

pegfilgrastim-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

pegfilgrastim-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

pegfilgrastim-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

pegfilgrastim-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

romyelocel-L-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

ST-7-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

tamibarotene-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Neutropenia-Recent Pipeline Updates 79

Neutropenia-Dormant Projects 83

Neutropenia-Product Development Milestones 85

Featured News & Press Releases 85

Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study 85

Feb 17, 2015: Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Filgrastim (Grastofil) 85

Dec 17, 2014: Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim 85

Jul 02, 2014: Application for the Additional Indication of Febrile Neutropenia for ZOSYN, an Injectable Antibiotic Combined with -Lactamase Inhibitor 86

Dec 09, 2013: Ligand Announces Positive Preclinical Data on Small-Molecule G-CSF Receptor Agonist at the 55th Annual Meeting of the American Society of Hematology 86

May 30, 2012: Aequus Presents Proof Of Concept Data Of GlycoPolymer Technology At International Symposium For Polymer Therapeutics 87

Dec 12, 2011: Ligand Announces Positive Preclinical Data On Small-Molecule GCSF Receptor Agonist At ASH Annual Meeting 88

Appendix 90

Methodology 90

Coverage 90

Secondary Research 90

Primary Research 90

Expert Panel Validation 90

Contact Us 90

Disclaimer 91

List of Tables

Number of Products under Development for Neutropenia, H1 2015 10

Number of Products under Development for Neutropenia-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Development by Companies, H1 2015 (Contd..1) 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Comparative Analysis by Unknown Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Neutropenia-Pipeline by Apotex, Inc., H1 2015 21

Neutropenia-Pipeline by Biocon Limited, H1 2015 22

Neutropenia-Pipeline by Biosidus S.A., H1 2015 23

Neutropenia-Pipeline by Cellerant Therapeutics, Inc., H1 2015 24

Neutropenia-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 25

Neutropenia-Pipeline by Coherus BioSciences, Inc., H1 2015 26

Neutropenia-Pipeline by CSL Limited, H1 2015 27

Neutropenia-Pipeline by Gamida Cell Ltd., H1 2015 28

Neutropenia-Pipeline by Genexine, Inc., H1 2015 29

Neutropenia-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 30

Neutropenia-Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 31

Neutropenia-Pipeline by NAL Pharmaceuticals Ltd., H1 2015 32

Neutropenia-Pipeline by Pfenex Inc., H1 2015 33

Neutropenia-Pipeline by Richter Gedeon Nyrt., H1 2015 34

Neutropenia-Pipeline by Sandoz International GmbH, H1 2015 35

Neutropenia-Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015 36

Neutropenia-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 37

Neutropenia-Pipeline by Therapeutic Proteins International, LLC, H1 2015 38

Neutropenia-Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2015 39

Neutropenia-Pipeline by USV Limited, H1 2015 40

Assessment by Monotherapy Products, H1 2015 41

Assessment by Combination Products, H1 2015 42

Number of Products by Stage and Target, H1 2015 44

Number of Products by Stage and Mechanism of Action, H1 2015 46

Number of Products by Stage and Route of Administration, H1 2015 48

Number of Products by Stage and Molecule Type, H1 2015 50

Neutropenia Therapeutics-Recent Pipeline Updates, H1 2015 79

Neutropenia-Dormant Projects, H1 2015 83

Neutropenia-Dormant Projects (Contd..1), H1 2015 84

List of Figures

Number of Products under Development for Neutropenia, H1 2015 10

Number of Products under Development for Neutropenia-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 15

Assessment by Monotherapy Products, H1 2015 41

Number of Products by Top 10 Targets, H1 2015 43

Number of Products by Stage and Top 10 Targets, H1 2015 44

Number of Products by Top 10 Mechanism of Actions, H1 2015 45

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 46

Number of Products by Top 10 Routes of Administration, H1 2015 47

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 48

Number of Products by Top 10 Molecule Types, H1 2015 49

Number of Products by Stage and Top 10 Molecule Types, H1 2015 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Apotex, Inc.

Biocon Limited

Biosidus S.A.

Cellerant Therapeutics, Inc.

Chong Kun Dang Pharmaceutical Corp.

Coherus BioSciences, Inc.

CSL Limited

Gamida Cell Ltd.

Genexine, Inc.

Inbiopro Solutions Pvt. Ltd.

Ligand Pharmaceuticals, Inc.

NAL Pharmaceuticals Ltd.

Pfenex Inc.

Richter Gedeon Nyrt.

Sandoz International GmbH

Taiho Pharmaceutical Co., Ltd.

Teva Pharmaceutical Industries Limited

Therapeutic Proteins International, LLC

Toko Pharmaceutical Industries Co., Ltd.

USV Limited

Neutropenia Therapeutic Products under Development, Key Players in Neutropenia Therapeutics, Neutropenia Pipeline Overview, Neutropenia Pipeline, Neutropenia Pipeline Assessment

select a license

Single User License
USD 2000 INR 133180
Site License
USD 4000 INR 266360
Corporate User License
USD 6000 INR 399540



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]